Two leases on LIF
How Northern targets both tumor immunosuppression and self-renewal
While most immuno-oncology products in the clinic target the immunosuppressive factors that help tumors evade an attack, Northern Biologics Inc.'s anti-LIF antibody takes a step further. By simultaneously blocking both immunosuppression and self-renewal of cancer stem cells the newco expects the antibody to be effective against a wider range of cancers than other immuno-oncology programs.
Northern was launched in 2014 by Versant Ventures to develop cancer and fibrosis